Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Probable adipokine. Additionally we are shipping C1q and Tumor Necrosis Factor Related Protein 9 Kits (17) and C1q and Tumor Necrosis Factor Related Protein 9 Proteins (7) and many more products for this protein.
Showing 10 out of 27 products:
Results demonstrate that CTRP9 alleviates hepatic steatosis through relief of endoplasmic reticulum stress via the AMPK (show PRKAA1 Antibodies)-mediated induction of autophagy.
Study demonstrates that CTRP9 attenuates cytokine-induced vascular inflammation in endothelial cells mediated by AMPK (show PRKAA1 Antibodies) activation.
Circulating and coronary CTRP9 plays an important role in the inflammation and coronary atherosclerosis of CAD (show CAD Antibodies) patients. Serum CTRP9 is an independent protective factor of CAD (show CAD Antibodies)
Serum CTRP9 concentration was significantly and positively associated with arterial stiffness in patients with type 2 diabetes
Serum CTRP9 concentrations were positively associated with favorable glucose or metabolic phenotypes and absence of metabolic syndrome, independent of serum total adiponectin (show ADIPOQ Antibodies) concentrations.
Suggest reduced plasma CTRP9 concentration during diabetes plays a causative role in platelet hyper-activity, contributing to platelet-induced cardiovascular damage.
Enhancing cardiac CTRP9 production and/or its proteolytic posttranslational modification are of therapeutic potential, attenuating diabetic cardiac injury.
CTRP9 protects against acute cardiac damage in response to pathological stimuli by suppressing inflammatory reactions through AdipoR1 (show ADIPOR1 Antibodies)/AMPK (show PRKAA1 Antibodies)-dependent mechanisms.
CTRP9 reduces pro-inflammatory cytokines expression in atherosclerotic plaque.
Genetic evidence for a physiological role of CTRP9 in controlling energy balance via central and peripheral mechanisms.
Adipokine CTRP9 attenuates adverse cardiac remodeling after acute myocardial infarction, largely via a protein kinase A (PKA)-dependent pathway.
data indicate that CTRP9 functions to attenuate neointimal formation following vascular injury through its ability to inhibit VSMC growth via cAMP-dependent mechanism
CTRP9 protects against acute cardiac injury following ischemia-reperfusion via an AMPK (show PRKAA1 Antibodies)-dependent mechanism.
We have provided the first evidence that CTRP9 is a novel vasorelaxative adipocytokine that may exert vasculoprotective effects via the adiponectin receptor 1 (show ADIPOR1 Antibodies)/AMPK (show PRKAA1 Antibodies)/eNOS (show NOS3 Antibodies) dependent/NO mediated signaling pathway.
Probable adipokine. Activates AMPK, AKT, and p44/42 MAPK signaling pathways (By similarity).
complement C1q and tumor necrosis factor-related protein 9
, complement C1q and tumor necrosis factor-related protein 9A
, complement C1q tumor necrosis factor-related protein 9
, complement C1q tumor necrosis factor-related protein 9A